This combination may support recovery, sleep quality, body composition, and long-term metabolic goals when used under medical supervision
The Harmony Outcomes trial further revealed that albiglutide reduced MACE by 22% over a median follow-up period of 1.6 years in patients with type 2 diabetes and cardiovascular disease ( p = 0.0006) [70]
Although GLP-1 has been studied for decades, public interest has skyrocketed with the introduction of medications such as Ozempic, Wegovy, and Mounjaro, which target this hormone to help manage blood sugars and support weight loss
Regular check-ups, symptom monitoring, and open communication with your healthcare provider can all support better long-term health, improved sleep, and overall well-being.